May 26-28: Society for Interdisciplinary Placebo Studies' Third International Conference
April 13, 2021UMB will host the third International Conference of the Society for Interdisciplinary Placebo Studies (SIPS), “Harnessing Placebo Mechanisms for Optimal Pain Management and Treatment of Alcohol and Other Drug Use Disorders," virtually, May 26-28. The cost to attend is $15 for UMB employees.
Expert faculty from UMB's Schools of Medicine, Nursing, and Pharmacy have collaborated with SIPS to design an interdisciplinary, international scientific conference to advance the science of placebo research and mind-body mechanisms and to apply this knowledge to alcohol use and pain disorders.
The conference will provide a collaborative platform to present and share innovative research findings and theoretical ideas on placebo research to an international audience of researchers; promote training and education of trainees, academic junior researchers, health care professionals, agencies, stakeholders, and the public; and advocate for the participation of minorities and women while expanding U.S. research in the global network of placebo research.
The program will include:
- Seven plenary sessions
- Three special sessions on COVID-19, placebo methodology, and virtual reality
- Over 20 workshops
- Peer-reviewed short oral presentations
- Peer-reviewed poster sessions
- Networking forums
Continuing education (CE) credit will be available for physicians, nurses, and pharmacists.
Presentations to include Plenary lecture 5: Negative emotional state neuroadaptations in addiction and how they can become conditioned to cues and context by George Koob, PhD, director, National Institute on Alcohol Abuse and Alcoholism (NIAAA), with an introduction by Joanne B. Fertig, PhD, acting deputy director, Division of Medications Development, NIAAA.
Koob is an internationally recognized expert on the neurobiology of alcohol and drug addiction and stress. As the NIAAA director, he provides leadership in the national effort to reduce the public health burden associated with alcohol misuse. He oversees a broad portfolio of alcohol research ranging from basic science to epidemiology, diagnostics, prevention, and treatment.